tetano
Editor, Senior Moderator
Stem Cell Res Ther
. 2022 Jul 16;13(1):321.
doi: 10.1186/s13287-022-02972-3.
One-year follow-up study after patients with severe COVID-19 received human umbilical cord mesenchymal stem cells treatment
Lei Shi[SUP] #[/SUP][SUP] 1 2 [/SUP], You Zheng[SUP] #[/SUP][SUP] 3 [/SUP], Zhi Cheng[SUP] #[/SUP][SUP] 4 [/SUP], Ningfei Ji[SUP] #[/SUP][SUP] 5 [/SUP], Changming Niu[SUP] 4 [/SUP], Yan Wang[SUP] 6 [/SUP], Tingrong Huang[SUP] 3 [/SUP], Ruyou Li[SUP] 7 [/SUP], Mao Huang[SUP] 5 [/SUP], Xiaolin Chen[SUP] 2 [/SUP], Lei Shu[SUP] 2 [/SUP], Mingjing Wu[SUP] 2 [/SUP], Kaili Deng[SUP] 2 [/SUP], Jing Wei[SUP] 2 [/SUP], Xueli Wang[SUP] 2 [/SUP], Yang Cao[SUP] 2 [/SUP], Jiaxin Yan[SUP] 2 [/SUP], Ganzhu Feng[SUP] 8 [/SUP]
Affiliations
Abstract
Background: The novel coronavirus is still mutating, and the pandemic continues. Meanwhile, many COVID-19 survivors have residual postinfection clinical manifestations. Human umbilical cord mesenchymal stem cells (hUC-MSCs) have been shown to be effective in the early stages of COVID-19.
Objectives: The aim of this study was to investigate long-term safety and efficacy of treatment in patients with severe COVID-19 patients who had received hUC-MSCs therapy.
Methods: Twenty-five discharged patients who had severe COVID-19 (including the standard treatment group and the standard treatment plus hUC-MSCs group) were enrolled in a 1-year follow-up. The assessment considered adverse effects (including effects on liver and kidney function, coagulation, ECG, tumor marker, and so on), pulmonary function, St George's Respiratory Questionnaire (SGRQ), postinfection sequelae and serum concentration of Krebs von den Lungen-6 (KL-6), malondialdehyde (MDA), H[SUB]2[/SUB]S, carnitine, and N-6 long-chain polyunsaturated fatty acids (N-6 LC-PUFAs).
Measurements and main results: Pulmonary ventilation function had significantly improved at the 1-year follow-up in both the hUC-MSCs group and the control group compared with the 3-month follow-up (P < 0.01). Fatigue (60% [15/25]) remained the most common symptom at the 1-year follow-up. The rate of fatigue relief was significantly reduced in the hUC-MSCs group (25% [2/8]) compared to the control group (76.5% [13/17]) (P = 0.028). The level of KL-6 was significantly lower in the hUC-MSCs group (2585.5 ± 186.5 U/ml) than in the control group (3120.7 ± 158.3 U/ml) (P < 0.001). Compared with the control group, the hUC-MSCs group had a lower level of MDA (9.27 ± 0.54 vs. 9.91 ± 0.72 nmol/ml, P = 0.036). No obvious adverse effects were observed in the hUC-MSCs treatment group at 1 year after discharge.
Conclusions: Intravenous transplantation of hUC-MSCs was a safe approach in the long term in the treatment of patients with severe COVID-19. In addition, hUC-MSCs had a positive effect on postinfection sequelae in COVID-19 survivors.
Trial registration: Chinese Clinical Trial Registration; ChiCTR2000031494; Registered 02 April 2020-Retrospectively registered, http://www.medresman.org.
Keywords: 1-Year follow-up; Coronavirus disease 2019 (COVID-19); Human umbilical cord mesenchymal stem cells (h-UC-MSCs); Safety; Sequelae.
. 2022 Jul 16;13(1):321.
doi: 10.1186/s13287-022-02972-3.
One-year follow-up study after patients with severe COVID-19 received human umbilical cord mesenchymal stem cells treatment
Lei Shi[SUP] #[/SUP][SUP] 1 2 [/SUP], You Zheng[SUP] #[/SUP][SUP] 3 [/SUP], Zhi Cheng[SUP] #[/SUP][SUP] 4 [/SUP], Ningfei Ji[SUP] #[/SUP][SUP] 5 [/SUP], Changming Niu[SUP] 4 [/SUP], Yan Wang[SUP] 6 [/SUP], Tingrong Huang[SUP] 3 [/SUP], Ruyou Li[SUP] 7 [/SUP], Mao Huang[SUP] 5 [/SUP], Xiaolin Chen[SUP] 2 [/SUP], Lei Shu[SUP] 2 [/SUP], Mingjing Wu[SUP] 2 [/SUP], Kaili Deng[SUP] 2 [/SUP], Jing Wei[SUP] 2 [/SUP], Xueli Wang[SUP] 2 [/SUP], Yang Cao[SUP] 2 [/SUP], Jiaxin Yan[SUP] 2 [/SUP], Ganzhu Feng[SUP] 8 [/SUP]
Affiliations
- PMID: 35842684
- DOI: 10.1186/s13287-022-02972-3
Abstract
Background: The novel coronavirus is still mutating, and the pandemic continues. Meanwhile, many COVID-19 survivors have residual postinfection clinical manifestations. Human umbilical cord mesenchymal stem cells (hUC-MSCs) have been shown to be effective in the early stages of COVID-19.
Objectives: The aim of this study was to investigate long-term safety and efficacy of treatment in patients with severe COVID-19 patients who had received hUC-MSCs therapy.
Methods: Twenty-five discharged patients who had severe COVID-19 (including the standard treatment group and the standard treatment plus hUC-MSCs group) were enrolled in a 1-year follow-up. The assessment considered adverse effects (including effects on liver and kidney function, coagulation, ECG, tumor marker, and so on), pulmonary function, St George's Respiratory Questionnaire (SGRQ), postinfection sequelae and serum concentration of Krebs von den Lungen-6 (KL-6), malondialdehyde (MDA), H[SUB]2[/SUB]S, carnitine, and N-6 long-chain polyunsaturated fatty acids (N-6 LC-PUFAs).
Measurements and main results: Pulmonary ventilation function had significantly improved at the 1-year follow-up in both the hUC-MSCs group and the control group compared with the 3-month follow-up (P < 0.01). Fatigue (60% [15/25]) remained the most common symptom at the 1-year follow-up. The rate of fatigue relief was significantly reduced in the hUC-MSCs group (25% [2/8]) compared to the control group (76.5% [13/17]) (P = 0.028). The level of KL-6 was significantly lower in the hUC-MSCs group (2585.5 ± 186.5 U/ml) than in the control group (3120.7 ± 158.3 U/ml) (P < 0.001). Compared with the control group, the hUC-MSCs group had a lower level of MDA (9.27 ± 0.54 vs. 9.91 ± 0.72 nmol/ml, P = 0.036). No obvious adverse effects were observed in the hUC-MSCs treatment group at 1 year after discharge.
Conclusions: Intravenous transplantation of hUC-MSCs was a safe approach in the long term in the treatment of patients with severe COVID-19. In addition, hUC-MSCs had a positive effect on postinfection sequelae in COVID-19 survivors.
Trial registration: Chinese Clinical Trial Registration; ChiCTR2000031494; Registered 02 April 2020-Retrospectively registered, http://www.medresman.org.
Keywords: 1-Year follow-up; Coronavirus disease 2019 (COVID-19); Human umbilical cord mesenchymal stem cells (h-UC-MSCs); Safety; Sequelae.